A federal judge rejected Novo’s attempt to block Lilly’s obesity drug advertising campaign, finding Novo failed to show that the ad claims caused meaningful harm to Novo’s sales in Denmark. The decision maintains Lilly’s marketing posture for its obesity product claims and limits Novo’s ability to prevent the campaign through injunctive relief. The ruling focuses on whether Novo proved a sufficient linkage between the contested advertising statements and measurable commercial damage. With the court declining to halt the campaign, Novo’s dispute shifts toward ongoing regulatory and commercial channels rather than immediate ad restrictions. For competitors in obesity medicine, the outcome is a reminder that litigation over comparative claims can be difficult unless companies can show concrete sales impact. The case also signals that US- and EU-style “superiority” advertising disputes continue to be adjudicated in ways that can change messaging strategy quickly for branded obesity therapies.